BridgeBio Pharma (BBIO) announced significant clinical outcomes for acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The drug showed a 59% risk reduction in variant ATTR-CM patients and 31.2% reduction in wild-type ATTR-CM patients for the composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH).
Key highlights from the ATTRibute-CM Phase 3 trial include:
- Hazard ratio of 0.41 for ATTRv-CM patients
- 42% reduction in composite ACM and recurrent CVH events at Month 30
- 50% reduction in cumulative CVH events at Month 30
- Benefits observed in as few as 3 months
Acoramidis, approved as Attruby™ in the US and BEYONTTRA™ in Europe and Japan, demonstrates near-complete (≥90%) TTR stabilization. The drug showed improved outcomes in both variant and wild-type ATTR-CM patients, with statistically significant results in both subgroups.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.